한국어
English
日本語
中文(简体)
Iclusig 15 mg Tablets (Ponatinib Hydrochloride)
16.03mg
Tablet · Prescription medication
Otsuka Pharmaceutical Co., Ltd.
Ponatinib hydrochloride is an antineoplastic agent used in the treatment of certain leukemias.
MFDS ingredient code M265056
Ponatinib hydrochloride is an antineoplastic agent belonging to the tyrosine kinase inhibitor class, used in the treatment of certain hematological cancers such as chronic myeloid leukemia. This agent blocks the signaling pathways for cancer cell growth, thereby inhibiting the proliferation of cancer cells.
Ponatinib hydrochloride inhibits a specific enzyme within cancer cells known as tyrosine kinase, blocking the signals for cancer cells to grow or divide. As a result, the proliferation of cancer cells is halted, and apoptosis is promoted.
Approved uses differ by product. Check each product's information for its actual use.
Unlike other tyrosine kinase inhibitors, ponatinib hydrochloride can effectively inhibit various mutant forms of the BCR-ABL protein, making it suitable for patients who have developed resistance to prior treatments.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
